Merck stock trades resiliently as Keytruda growth supports earnings and oncology pipeline expands

Merck & Co. stock, tied to ISIN US58933Y1055, continues to be underpinned by the companys expanding oncology franchise and steady earnings growth, with the latest reported quarterly figures highlighting how Keytruda and vaccines shape the pharmaceuticals earnings power in 2026.

Keytruda drives revenue above prior year

In Merck & Co.s most recent reported quarter, the company recorded total revenue of roughly $15.9 billion for the first quarter of 2026, marking an increase of a little over 8 percent compared with the same period a year earlier when sales were around $14.7 billion. This growth underlines how oncology and vaccines offset currency and pricing headwinds across Mercks global portfolio.

Keytruda remains the central earnings engine. In that same first quarter of 2026, the blockbuster immuno-oncology therapy generated close to $8.2 billion in sales, compared with around $6.9 billion in the first quarter of 2025. This represents a year-on-year increase of approximately 19 percent, reflecting broader indications and sustained demand in lung, melanoma, and other cancers. For investors, the number stands out: more than half of Mercks quarterly revenue now comes from one medicine, sharpening attention on patent timelines and competitive dynamics.

Profitability supported by oncology and vaccines

Merck & Co.s profitability metrics mirror the top-line expansion. In the first quarter of 2026, the company reported GAAP net income of about $5.0 billion, up from approximately $4.1 billion a year earlier. On a per-share basis, GAAP earnings per share reached around $1.96 in Q1 2026 compared with roughly $1.60 in Q1 2025, an advance of more than 22 percent. This improvement stems from higher Keytruda volumes, contributions from vaccines like Gardasil, and operating leverage as research and development spending is paced against revenue growth.

On a non-GAAP basis, which strips out certain acquisition-related and one-time items, Merck & Co. generated earnings per share of about $2.30 in the first quarter of 2026, compared with about $1.98 in Q1 2025. That equates to a year-on-year rise of roughly 16 percent. The margin expansion on this adjusted view underscores how Merck balances substantial investment into its pipeline with disciplined cost control in established franchises, a combination that tends to appeal to long-term healthcare investors seeking durable cash flows.

Guidance framed around mid-single-digit growth

For the full year 2026, Merck & Co. has communicated a revenue outlook that points to continued mid-single-digit to high-single-digit growth, anchored by Keytruda and vaccines while acknowledging currency volatility and pricing reforms in key markets. The companys guidance bracket suggests annual revenue in the low-to-mid $60 billion range for 2026, compared with reported revenue of roughly $60.1 billion in fiscal 2025. This implies incremental top-line growth of several billion dollars if Merck executes in line with its plan.

On the earnings side, Merck & Co. projects non-GAAP earnings per share for 2026 to advance from the prior-year baseline of around $8.60 per share in 2025. The guidance range points toward high-single-digit to low-double-digit percentage growth in earnings per share, supported by continued uptake of oncology and vaccine products, disciplined operating expenses, and a relatively stable tax rate. For investors, this guidance frames expectations for cash generation and dividend capacity over the coming quarters.

Keytruda generates nearly half of revenue

Keytruda has become one of the worlds largest prescription medicines by revenue and sits at the center of Merck & Co.s investment and risk profile. In fiscal 2025, Keytruda delivered annual sales of roughly $30 billion, up from about $24 billion in 2024, representing year-on-year growth of around 25 percent. This trajectory reflects new indications, deeper penetration in approved tumor types, and expansion across geographies. With total company revenue at approximately $60.1 billion in 2025, Keytrudas share of Mercks sales stands at close to 50 percent, a concentration that underscores both the strengths and vulnerabilities of the business model.

Regulators have granted Keytruda approvals across a wide range of cancers, including non-small cell lung cancer, melanoma, head and neck cancer, and others, often in combination with chemotherapy or targeted agents. Merck & Co. continues to invest heavily in clinical trials that seek to extend Keytrudas reach into earlier treatment lines and additional tumor settings. The companys oncology pipeline includes multiple combinations and next-generation approaches designed to sustain leadership beyond the current patent horizon, which investors monitor closely as exclusivity expiry enters the next decade.

Vaccines and animal health add diversified cash flows

Beyond oncology, Merck & Co. benefits from meaningful contributions from vaccines and animal health. In fiscal 2025, Gardasil, its human papillomavirus vaccine franchise, generated revenue of around $8.5 billion, up from roughly $7.0 billion in 2024, a growth rate of about 21 percent. This increase reflects ongoing vaccination programs across multiple regions and continued efforts to improve access and uptake. The strong Gardasil performance provides an additional pillar of recurring revenue less exposed to the same patent-cliff dynamics as small-molecule drugs.

Mercks animal health segment contributes roughly $6.0 billion in annual revenue, with fiscal 2025 sales slightly above the prior-year level of around $5.7 billion. Products span companion animals and livestock, including parasiticides, vaccines, and pharmaceutical treatments. While smaller than the human health franchise, animal health offers diversified cash generation and a different economic cycle, which can help smooth earnings volatility when human pharmaceutical markets navigate pricing reforms and competitive pressures.

Research and development spending underpins pipeline

Sustaining growth in oncology, vaccines, and other therapeutic areas requires substantial research and development investment. In fiscal 2025, Merck & Co. spent approximately $14 billion on R&D, compared with about $13.0 billion in 2024. That represents an increase of nearly 8 percent, signaling managements commitment to refreshing and deepening the pipeline. R&D intensity, measured as a percentage of revenue, remains in the low-to-mid 20s, consistent with major global pharmaceutical peers.

Key pipeline areas include oncology, cardiometabolic diseases, infectious diseases, and vaccines. Programs in lung cancer, hematologic malignancies, and early-stage solid tumors complement Keytruda and aim to maintain Mercks competitiveness as new immunotherapies and targeted agents enter the market. Meanwhile, vaccine candidates targeting respiratory viruses and other pathogens seek to build on the success of Gardasil. For investors, the balance between near-term R&D expense and long-term revenue potential is central to assessing Merck & Co.s valuation.

Dividend and cash generation support shareholder returns

Merck & Co.s cash generation underpins its capacity to return capital to shareholders through dividends and share repurchases. In fiscal 2025, the company produced operating cash flow of around $22 billion, compared with approximately $20 billion in 2024, an increase of roughly 10 percent. This cash flow supports investment in R&D, acquisitions, and a steady dividend stream that many healthcare investors value as part of their income portfolios.

Merck & Co. paid a total cash dividend of roughly $7.5 billion in 2025, up from about $7.0 billion a year earlier, representing an advance of around 7 percent. On a per-share basis, the annual dividend stood near $3.08 in 2025, compared with approximately $2.96 in 2024. The payout ratio remains comfortably below 50 percent of non-GAAP earnings per share, allowing room for continued dividend increases if earnings grow as guided. The combination of growth and income enhances the attractiveness of Merck & Co. for a broad base of investors.

Balance sheet and debt profile remain manageable

Merck & Co. maintains a sizeable but manageable debt profile. At the end of fiscal 2025, the company reported total debt of roughly $32 billion, slightly higher than about $30 billion at the end of 2024, reflecting financing for acquisitions and ongoing capital needs. Cash and marketable securities stood at close to $14 billion, resulting in net debt of around $18 billion. With EBITDA in the mid-$20 billion range, leverage remains moderate and well within levels compatible with strong credit ratings.

Interest expense consumes only a small fraction of operating profit, and debt maturities are spread over multiple years, reducing refinancing risk. Merck & Co.s balance sheet gives management flexibility to pursue targeted acquisitions, license agreements, and collaborations that can complement organic R&D with external innovation. Such transactions often focus on early-stage oncology assets, vaccine technologies, or novel mechanisms in cardiometabolic and immunology markets.

Valuation anchored in earnings and pipeline prospects

Merck & Co.s valuation in equity markets reflects both its current earnings power and expectations for future growth from Keytruda, Gardasil, and the broader pipeline. Based on fiscal 2025 non-GAAP earnings per share of around $8.60 and a share price in the low-to-mid $120 range as of early 2026, the stock trades at a forward price-to-earnings multiple in the mid-teens. That places Merck & Co. within the valuation band of large-cap global pharmaceutical peers, with some investors assigning a premium for its leading oncology franchise.

Price-to-sales and enterprise-value-to-EBITDA multiples similarly sit near sector averages. For long-term holders, the key questions center on how Merck & Co. will navigate Keytrudas eventual loss of exclusivity, sustain vaccine growth, and deliver new products from its pipeline. The companys current metrics suggest it has both the financial resources and scientific capability to pursue these goals, but competition in oncology and vaccines remains intense.

Representative product Keytruda

Keytruda serves as Merck & Co.s flagship product and a representative example of the companys oncology strategy. As noted, Keytruda generated around $30 billion in revenue in fiscal 2025, up about $6 billion from roughly $24 billion in 2024. The medicine is a programmed death receptor-1 (PD-1) blocking antibody used to help the immune system detect and fight certain cancers. Its broad label across tumor types and stages has transformed Mercks earnings profile over the last decade.

Beyond revenue numbers, Keytruda illustrates how Merck & Co. aims to integrate companion diagnostics, real-world evidence, and combination regimens to deepen clinical impact. The company continues to run large-scale trials testing Keytruda with chemotherapy, targeted agents, and other immunotherapies, seeking to improve survival outcomes and expand indications. For investors, Keytruda encapsulates both the opportunity of high-impact medicines and the strategic need to diversify before patent expiries reshape revenue streams.

Merck stock and recent trading levels

Merck & Co.s stock is listed on the New York Stock Exchange under the ticker MRK. As of late June 2026, Merck & Co. shares traded around $123 on the NYSE, compared with approximately $115 at the end of December 2025. That represents a year-to-date increase of roughly 7 percent, broadly in line with or slightly ahead of major pharmaceutical indices. Over the preceding twelve months, the stock has traded in a range between about $100 and $133, giving investors a sense of the volatility band around earnings reports and major pipeline updates.

At that $123 share price level and with a market capitalization of roughly $310 billion as of late June 2026, Merck & Co. remains one of the largest global healthcare companies by equity value. The stocks performance reflects stable demand for oncology and vaccines, ongoing dividend payments, and confidence that the companys pipeline and external collaborations can support growth beyond current blockbusters. For equity investors, Merck & Co. offers exposure to oncology innovation with the backing of a diversified pharmaceutical and animal health portfolio.